All News

2 June 2008

ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung CancerAntibodies

2 June 2008

Study confirms that Avastin significantly increases chance of living without disease progression in metastatic breast cancerAntibodies

30 May 2008

Genmab initiates Zalutumunab combination study in Colorectal CancerAntibodies

30 May 2008

Continuing Herceptin treatment prevents disease progression in women with aggressive metastatic breast cancerAntibodies

30 May 2008

Merck Receives CHMP Positive Opinion for Marketing Authorization for Erbitux Including First-Line Colorectal Cancer in the European UnionAntibodies

28 May 2008

Ablynx Announces Initiation of a Phase Ib Study in Patients for ALX-0081 and Provides a Business Update for the First Quarter 2008Antibodies

28 May 2008

Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))Antibodies

21 May 2008

Cimzia(R) provides long-term efficacy with stable dosing in Crohn’s diseaseAntibodies

21 May 2008

Sanofi-aventis and Regeneron Update Aflibercept (VEGF Trap) Clinical Development Program in OncologyAntibodies

21 May 2008

Medarex Reports Phase 1 Clinical Data of MDX-1100 at Digestive Disease WeekAntibodies

20 May 2008

Phase I/II Studies of IMC-A12 in Pancreatic Cancer Open for Patient EnrollmentAntibodies

20 May 2008

Denosumab Osteoporosis Study Meets Primary and All Secondary Bone Mineral Density Endpoints in Alendronate (FOSAMAX(R)) Transition StudyAntibodies

19 May 2008

Schering-Plough Extends Antibody Alliance with MorphoSysAntibodies

19 May 2008

Patient recruitment started in Phase III registration trial with CA9-SCANAntibodies

16 May 2008

ERBITUX(R) (cetuximab) Data Demonstrate Improvements in Response Rate and Progression-Free Survival in Wild Type K-Ras Metastatic Colorectal Cancer Patients in First-Line SettingAntibodies

15 May 2008

Lpath’s iSONEP(TM) IND Application Gets Green Light From FDAAntibodies

13 May 2008

Active Biotech advances ANYARA into Phase III clinical trialAntibodies

13 May 2008

Start of Phase II Clinical Study for Rabies Monoclonal Antibody Combination in the PhilippinesAntibodies

13 May 2008

Affimed validates antibody target for cancer metastasisAntibodies

13 May 2008

Phase II Study of IMC-A12 for Advanced Liver Cancer Opens for Patient EnrollmentAntibodies

12 May 2008

Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid ArthritisAntibodies

9 May 2008

Actemra inhibits joint damage and improves physical function of patients with Rheumatoid ArthritisAntibodies

8 May 2008

Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid ArthritisAntibodies

8 May 2008

Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye in Wet Age-related Macular DegenerationAntibodies

30 April 2008

Merck Serono and ZymoGenetics Initiate Atacicept Phase 2 Clinical Trial in Relapsing Multiple SclerosisAntibodies

29 April 2008

Genentech and Biogen Idec Announce Top-Line Results From Phase II/III Clinical Study of Rituxan in Systemic Lupus ErythematosusAntibodies

29 April 2008

Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Bavituximab Phase II Breast Cancer TrialAntibodies

28 April 2008

Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of IpilimumabAntibodies

28 April 2008

KaloBios Completes Patient Dosing in its U.S. Phase 1 Trial of Its Third Drug Candidate, KB003Antibodies

28 April 2008

Regeneron and Bayer HealthCare Announce Encouraging 32-Week Follow-Up Results from a Phase 2 Study of VEGF Trap-Eye in Age-Related Macular DegenerationAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

PSMA-Targeted Therapy Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

FcRn Inhibitors Pipeline Review

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA